Urinary Tract Infection Extended Spectrum β Lactamase (ESBL) in Pediatric Patients: Mono-centric Hospital Study in Lebanon between 2012 and 2017
Himalayan Journal of Medicine and Surgery · 10.01.2021 · 02 (01) · 1-16
DOI: 10.47310/hjms.2021.v02i01.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Himalayan Journal of Medicine and Surgery, online erschienen am 10.01.2021. Verfasst von Rouwayda Dana und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Background and Objective: Urinary tract infections (UTIs) are very common among children and could have long-term complications if not diagnosed and treated promptly. The aim of this study was to determine the prevalence of UTI caused by extended spectrum β lactamase (ESBL)-producing organisms in Lebanese pediatric patients between 2012 and 2017. Subjects and Methods: Data was collected from the medical records at Rafik Hariri University Hospital concerning some demographics, clinical and diagnostic characteristics of the patients. SPSS was used for statistical analysis using descriptive as well as tests like Chi-square, Fisher’s and independent samples Mann Whitney U test.
Results
Out of the total 211 patients, the majority were females (70.2%), 47.3% were Lebanese, and 44.1% were Syrians. Mean age was 2.85 years. We found that 40.7% had systemic diseases, 41.8% were previously using antibiotics, 30.3% were pre-hospitalized within a month, 15.3% were immunocompromised, and only 3.9% had a past history of constipation. Also, 26.3% had a recurrent UTI. The major symptom (58%) was fever above 38.3 °C and 13.6% of the enrolled patients were admitted to ICU. The most common uropathogen was E. coli (70%) and 7% of the uropathogens were resistant to Carbapenem. Alarming resistances were noted for Ampicillin (90.3%) followed by Cefalotin (71.4%) while no resistance was noted for Colistin, and Fosfomycin (0%). Patients infected with ESBL had longer hospital length of stay than those with non-ESBL-producing E. coli (P-value = 0.002). Significant difference in hospital length of stay was noted between patients treated with Imipenem (Tienam®) or Meropenem (Meronem®) before culture results and those who weren’t (P-value < 0.001).
Conclusion
UTI and the emerging resistance in ESBL-producing organisms are challenging as the antibiotic therapy options and being limited leading to increased hospitalization. Recommendations to guide the prescription of antibiotics and management of UTI are essential to prevent sequelae in pediatric UTI patients.
Zitieren
APA
Dana, R., Merhi, B. A., Kalach, Z. A., Sabsabi, S. A., & Lagha, J. (2021). Urinary Tract Infection Extended Spectrum β Lactamase (ESBL) in Pediatric Patients: Mono-centric Hospital Study in Lebanon between 2012 and 2017. Himalayan Journal of Medicine and Surgery, 02(01), 1-16. https://doi.org/10.47310/hjms.2021.v02i01.001
Vancouver
Dana R, Merhi BA, Kalach ZA, Sabsabi SA, Lagha J. Urinary Tract Infection Extended Spectrum β Lactamase (ESBL) in Pediatric Patients: Mono-centric Hospital Study in Lebanon between 2012 and 2017. Himalayan Journal of Medicine and Surgery. 2021;02(01):1-16. doi:10.47310/hjms.2021.v02i01.001
BibTeX
@article{Dana2021,
author = {Dana, Rouwayda and Merhi, Bassem Abou and Kalach, Zaynab Abed and Sabsabi, Sajida Al and Lagha, Jouhayna},
title = {Urinary Tract Infection Extended Spectrum β Lactamase (ESBL) in Pediatric Patients: Mono-centric Hospital Study in Lebanon between 2012 and 2017},
journal = {Himalayan Journal of Medicine and Surgery},
year = {2021},
volume = {02},
number = {01},
pages = {1--16},
doi = {10.47310/hjms.2021.v02i01.001}
}
EUVIMED